Revenue

Infrastructure software giant posts 11% revenue growth, outlines a bullish 2026 forecast, and doubles down on AI with key acquisitions.

A new partnership brings AI to customs, promising to help U.S. importers reclaim millions in overpaid duties and navigate volatile global trade.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

Robert Herjavec invests in AI firm Lovelytics, betting on the critical need for data infrastructure and aiming to scale the top Databricks partner.

As a 24-year CEO era ends, McCoy Global bets on an internal tech architect to lead its future in automated well construction and maintain growth.

On the war's fourth anniversary, Kyivstar's board, including Mike Pompeo, visited Kyiv, reaffirming a $1B investment and honoring resilient employees.

As Matricelf presents its breakthrough therapy at a major summit, the company moves closer to human trials, offering new hope for paralysis patients.

The burger chain posted robust revenue and a massive jump in annual net income, outperforming rivals and detailing plans for major global expansion.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Former USAA CEO Wayne Peacock joins Cotality's board, signaling a strategic push to lead the AI-driven property data and insurance analytics market.

A new partnership aims to capitalize on surging defense spending and supply chain shifts, signaling a new era for specialized private equity investing.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

Facing slow auto OEM cycles, Arbe Robotics names a new CEO and targets defense, robotaxis, and China to accelerate revenue from its high-res radar tech.

As colorectal cancer rates rise in younger adults, advocates demand provinces lower the screening age. But will policymakers act on the growing evidence?

In a market dominated by wood, one developer is betting on steel. Discover how cold-formed steel is creating stronger, safer, and more resilient homes.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

The energy giant unveils a massive capital plan to boost regulated assets, even as a $471M write-down on renewables reveals significant grid challenges.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.